Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Skin Res Technol ; 21(3): 284-90, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25087689

ABSTRACT

BACKGROUND: Lock-in thermal imaging is a thermographic method that is widely used in the nondestructive testing of materials. The technique allows detecting under the sample surface, small variations of the thermophysical properties in a noninvasive and noncontact manner. Surprisingly, this method has, to our knowledge, never been used in dermatology although it is particularly suited. METHODS: We present in this article the first lock-in thermal imaging setup dedicated to dermatological applications. The apparatus uses a temperature-modulated airflow to periodically stimulate the skin surface. The infrared images recorded by a high sensitive camera are demodulated according to the digital lock-in principle to compute a phase and amplitude image. RESULTS: First results obtained on benign skin lesions are presented. The images allow to detect small variations of the tissue thermophysical properties like for example, perfusion variations. Lock-in thermal imaging has the ability to reject disturbing thermal signals coming from subcutaneous tissues. The localization of the lesions is more accurate due the suppression of the lateral heat spreading. CONCLUSION: Lock-in thermal imaging is a promising method for the detection of lesions exhibiting modified thermophysical properties compared to the surrounding healthy skin.


Subject(s)
Skin Diseases, Vascular/diagnosis , Skin Diseases, Vascular/physiopathology , Skin Temperature , Telangiectasis/diagnosis , Telangiectasis/physiopathology , Thermography/instrumentation , Diagnosis, Computer-Assisted/instrumentation , Diagnosis, Computer-Assisted/methods , Equipment Design , Equipment Failure Analysis , Humans , Reproducibility of Results , Sensitivity and Specificity
2.
Dermatology ; 227(2): 186-8, 2013.
Article in English | MEDLINE | ID: mdl-24060704

ABSTRACT

Nevus of Ota is a unilateral, asymptomatic cutaneous and mucosal hyperpigmentation of the face that is congenital or may appear during childhood. We present a case of symptomatic acquired nevus of Ota in an adult, associated with intense pruritus, not described in the literature so far. A 32-year-old woman presented with brownish mottled macules which appeared on her face progressively over 8 days, following the distribution of the first and second divisions of the left trigeminal nerve and partially covering the iris and sclera of the left eye. She reported an intense pruritus in this area. We performed a biopsy on the left forehead, which confirmed the diagnosis of nevus of Ota. Specific stains and immunohistochemistry revealed increased numbers of mast cells. Ophthalmological tests showed acute acquired melanocytosis of the left iris and sclera. The origin of the nevus is still unclear. Several hypotheses suggest a reactivation of melanocytes during their migration from the neural crest. The pruritus reported in our patient may be explained by the increased quantity of mast cells observed in the lesion and/or neuronal stimulation of the ophthalmic and maxillary divisions of the fifth cranial nerve.


Subject(s)
Face , Nevus of Ota/diagnosis , Pruritus/etiology , Skin Neoplasms/diagnosis , Adult , Biopsy , Diagnosis, Differential , Female , Humans , Nevus of Ota/complications , Pruritus/diagnosis , Skin Neoplasms/complications
3.
Rev Med Suisse ; 7(289): 765-6, 768-71, 2011 Apr 06.
Article in French | MEDLINE | ID: mdl-21568099

ABSTRACT

Lentigo maligna (LM) and lentigo maligna melanoma (LMM) account for about 10% of all melanomas. They have distinct clinical and histological features as well as specific epidemiology, natural history, evolution, and genetics. Epidemiology of these tumors progressively concerns younger patients. Diagnostic and preparation of surgical removal of LM and LMM can now be optimized by new technologies of imaging, like dermoscopy or in vivo confocal reflectance microscopy. Surgery is the treatment of choice, but alternative options can be considered, especially for the elderly for whom the needs for efficiency and acceptability should be met.


Subject(s)
Hutchinson's Melanotic Freckle , Skin Neoplasms , Humans , Hutchinson's Melanotic Freckle/pathology , Hutchinson's Melanotic Freckle/therapy , Skin Neoplasms/pathology , Skin Neoplasms/therapy
5.
Ann Dermatol Venereol ; 136(4): 360-3, 2009 Apr.
Article in French | MEDLINE | ID: mdl-19361705

ABSTRACT

BACKGROUND: Scleroedema adultorum Buschke (SB) is a rare disease involving scleroedema of the neck and shoulders. It can extend to the rest of the trunk and the limbs but characteristically spares the extremities. Three types of SB are distinguished: the first is acute and develops after an infectious disease, the second is of insidious evolution and is associated with monoclonal gammopathy, and the third is associated with type 2 diabetes. PATIENTS AND METHODS: We report the case of a type 2 diabetic patient presenting with progressive, oedematous timbering of the trunk associated with impaired mobility, dysphagia and restrictive respiratory syndrome. SB was diagnosed on the basis of clinical presentation and histology. Treatment was mandatory because of the adverse impact of the disease. A therapy that would not worsen the patient's comorbidities had to be chosen. Intravenous immunoglobulins were thus initiated with excellent response as of the first cycle regarding trunk mobility and dysphagia. Cutaneous rigidity improved steadily until the end of treatment (eight cycles). CONCLUSION: Therapeutic abstention is the rule in SB if it has no severe functional repercussions. Nevertheless, there is no clearly indicated treatment once therapy becomes necessary. Control of underlying diabetes usually does not improve the scleroedema and the metabolic syndrome contraindicates most of the treatments reported in the literature. In this article, we suggest a new treatment of SB in the diabetic patient.


Subject(s)
Diabetes Mellitus, Type 2/complications , Immunoglobulins, Intravenous/therapeutic use , Scleredema Adultorum/drug therapy , Deglutition Disorders/etiology , Humans , Male , Middle Aged , Scleredema Adultorum/complications , Treatment Outcome
6.
Rev Med Suisse ; 3(109): 1119-23, 2007 May 02.
Article in French | MEDLINE | ID: mdl-17552270

ABSTRACT

Due to the early diagnosis, melanomas can be diagnosed in early stages. Most melanomas tend not to show morphological criteria of malignancy in the very early stages. They rather resemble benign moles. For patients with hundreds of atypical lesions, follow-up examinations using digital dermoscopy are very helpful. This technique enables the physician to monitor lesions and to detect microscopic change. Lesions with microscopic change are thought to be high risk lesions and should be removed this will represent important savings for the health system because this will allow to make the diagnosis of melanoma in earlier stages and to save costs for unnecessary surgery. In this article we are going to review the technique.


Subject(s)
Dermoscopy , Melanoma/pathology , Population Surveillance , Skin Neoplasms/pathology , Humans
7.
J Invest Dermatol ; 117(6): 1464-70, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11886510

ABSTRACT

Vitiligo is a cutaneous pigmentary disorder characterized by the loss of melanocytes. An autoimmune mechanism is strongly suspected to be involved in this affection given that it is frequently associated with autoimmune hormonal disorders, and because antibodies directed against melanocytic antigens are found in the serum of patients with vitiligo. We examined the role of cellular immunity in melanoma-associated vitiligo by expanding infiltrating lymphocytes from fresh biopsy specimens of vitiligo patches in melanoma patients. The vitiligo-infiltrating lymphocytes were almost exclusively T lymphocytes, and most were CD8(+). Following in vitro expansion, vitiligo-infiltrating lymphocytes remained predominantly CD8(+) and expressed the cutaneous homing receptor CLA. Furthermore, vitiligo-infiltrating lymphocytes had a clonal or oligoclonal T cell receptor profile, possibly reflecting specific antigenic stimulation. Finally, vitiligo- infiltrating lymphocytes specifically recognized differentiation antigens shared by normal melanocytes and melanoma cells. This direct demonstration of CD8(+) T cell involvement in vitiligo suggests that, in melanoma patients, vitiligo may be a visible effect of a spontaneous antitumoral immune response.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Melanoma/immunology , Skin Neoplasms/immunology , Vitiligo/immunology , Adult , Aged , Cell Differentiation/immunology , Epitopes , Humans , Male , Melanocytes/cytology , Melanocytes/immunology , Melanoma/complications , Melanoma/pathology , Middle Aged , Receptors, Antigen, T-Cell/immunology , Skin Neoplasms/complications , Skin Neoplasms/pathology , Skin Pigmentation/immunology , Vitiligo/etiology , Vitiligo/pathology
8.
J Med Chem ; 43(20): 3803-8, 2000 Oct 05.
Article in English | MEDLINE | ID: mdl-11020297

ABSTRACT

The design of heteroclytic antigens with high MHC binding capacity is of particular interest to overcome the weak immunogenicity of peptide epitopes derived from tissue antigens expressed by tumors. In the present study, double-substituted peptide analogues of the tumor-associated antigen MART-1(27-35) incorporating a substitution at a primary anchor residue and a beta-amino acid residue at different positions in the sequence were synthesized and evaluated for binding to the human histocompatibility class I molecule HLA-A2 and for recognition by tumor-infiltrating lymphocytes. Interestingly, by combining a Leu for Ala substitution at P2 (which alone is deleterious for antigenic activity) with a beta-amino acid substitution at a putative TCR contact residue, recognition by tumor-infiltrating lymphocytes was partially restored. The analogue [Leu(28),beta-HIle(30)]MART-1(27-35) displays both a higher affinity to HLA-A2 and a more prolonged complex stability compared to [Leu(28)]MART-1(27-35). Overall, these results suggest that double-substitution strategies and beta-amino acid replacements at putative TCR contact residues might prove useful for the design of epitope mimics with high MHC binding capacity.


Subject(s)
Epitopes/chemistry , HLA-A2 Antigen/metabolism , Lymphocytes, Tumor-Infiltrating/metabolism , Melanoma/chemistry , Neoplasm Proteins/chemistry , Peptide Fragments/chemical synthesis , Chromatography, High Pressure Liquid , Electrophoresis, Capillary , Humans , Isoantigens/chemistry , Isoantigens/metabolism , Magnetic Resonance Spectroscopy , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Tumor Cells, Cultured
9.
Hum Gene Ther ; 11(13): 1911-20, 2000 Sep 01.
Article in English | MEDLINE | ID: mdl-10986563

ABSTRACT

Replication-defective adenoviruses are arousing growing interest as both gene therapy and vaccine vectors. In a phase I clinical trial designed to evaluate the feasibility and tolerance of recombinant adenovirus (rAd)mediated gene transfer, we previously demonstrated that a single intratumoral injection of 10(9) PFU of rAd encoding the beta-galactosidase protein (Ad-beta-Gal) induced strong short-term (1-3 months) humoral, helper (Th1 type) and cytotoxic T cell responses specific for the transgene product in patients with advanced lung cancer. The purpose of the present study was to evaluate the persistence of long-lasting immunity to the transgene protein and in parallel, to assess patient immunocompetence revealed by responses to recall antigens (tetanus toxoid, purified protein derivative), viral pathogens (Epstein-Barr virus, influenza virus), and allogeneic antigens in mixed lymphocytic reactions. The beta-Gal-specific proliferative response declined rapidly in patients with progressive disease, as did responses to the other antigens. In contrast, a long-lasting proliferative response to beta-gal was maintained in an immunocompetent patient in complete remission 2 years after an injection of 108 PFU of Ad-beta-Gal. Anti-beta-Gal humoral (IgG and IgA) responses persisted notably, as did responses to TT and poliomyelytic antigens. While T cell effector cytotoxic responses specific for the viral peptides plummeted, the frequency of anti-beta-Gal CTL precursors remained particularly high, thus attesting to major immunization. Despite the impact of both advanced disease and chemotherapy on immunocompetence, we show the long-term persistence of immunity to the transgene protein vectorized by rAd.


Subject(s)
Adenoviridae/genetics , Genetic Therapy/methods , Lung Neoplasms/immunology , Lung Neoplasms/therapy , Antibody Formation , CD8-Positive T-Lymphocytes/immunology , Cell Division/drug effects , Cell Division/genetics , Cell Division/immunology , Follow-Up Studies , Herpesvirus 4, Human/immunology , Humans , Immunity, Cellular , Immunoglobulin A/blood , Immunoglobulin G/blood , Longitudinal Studies , Neutrophils/immunology , Neutrophils/virology , Orthomyxoviridae/immunology , Poliomyelitis/immunology , Reference Values , Tetanus Toxoid/immunology , beta-Galactosidase/genetics , beta-Galactosidase/pharmacology
10.
Int Immunol ; 11(8): 1351-6, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10421792

ABSTRACT

In the present study, we demonstrate that the non-classical MHC class I molecule HLA-G impairs specific cytolytic T cell functions in addition to its well-established inhibition of NK lysis. The antigen-specific cytotoxic T lymphocyte (CTL) response analyzed was mediated by CD8(+) T cells specific for the influenza virus matrix epitope, M58-66, presented by HLA-A2. The transfection of HLA-G1 cDNA in target cells carrying the M58-66 epitope reduced their lysis by these virus-specific CTL. This HLA-G-mediated inhibition of antigen-specific CTL lysis was (i) peptide dose dependent, (ii) reversed by blocking HLA-G with a specific mAb and (iii) still observed despite the blockade of HLA-E/CD94/NKG2A interaction. By inhibiting both CTL and NK functions, HLA-G appears to have an extensive role in immune tolerance.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Influenza A virus/immunology , Killer Cells, Natural/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Matrix Proteins/immunology , Blotting, Western , CD8-Positive T-Lymphocytes/immunology , Cytotoxicity Tests, Immunologic , Epitopes , Flow Cytometry , HLA-G Antigens , Humans , Immune Tolerance , Influenza A virus/chemistry , Receptors, Immunologic/immunology , Receptors, Immunologic/metabolism , Tumor Cells, Cultured
11.
Cancer Res ; 59(8): 1954-60, 1999 Apr 15.
Article in English | MEDLINE | ID: mdl-10213506

ABSTRACT

Nonclassical MHC class I HLA-G antigen expression is tissue specific and is thought to play a role in tolerance of the semiallogeneic fetus by the maternal immune system. Ectopic expression of HLA-G by tumor cells provides them with an additional mechanism of escape from immunosurveillance by host cytotoxic effector mechanisms. The aim of this study was to assess the expression of nonclassical HLA-G antigens in ex vivo human melanoma biopsies. HLA-G mRNA levels corresponding to both membrane-bound and soluble protein isoforms were analyzed in tumor specimens obtained from primary or metastatic melanomas of 23 patients. High levels of HLA-G transcription were detected in tumor specimens in 5 of 23 patients and found to be comparable in both lymph node and skin metastases. HLA-G mRNA transcript levels at tumor sites in 18 of these patients were compared with those in samples of their own healthy skin and were higher in the tumor tissue in 12 patients. Differential expression of mRNA transcripts corresponding to soluble and membrane-bound HLA-G was also observed in some tumor biopsies. HLA-G protein expression was detected in tumors that exhibited high levels of HLA-G transcription by immunofluorescence of frozen sections and Western blot analysis of both tumor and healthy skin biopsies, using anti-HLA-G-specific monoclonal antibodies. This work provides evidence that HLA-G gene transcription and protein expression can be up-regulated ex vivo in melanoma. Our finding that several of the tumors studied expressed high levels of HLA-G provides additional clues as to how a tumor can be selected in vivo to escape from cytotoxic antitumor responses, constituting a new parameter to be considered in the design of therapeutic approaches aimed at enhancing antitumor immune responses.


Subject(s)
Gene Expression Regulation, Neoplastic , HLA Antigens/genetics , Histocompatibility Antigens Class I/genetics , Melanoma/genetics , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm , Biopsy , Female , Genetic Variation , HLA Antigens/biosynthesis , HLA-G Antigens , Histocompatibility Antigens Class I/biosynthesis , Humans , Male , Melanoma-Specific Antigens , Middle Aged , Neoplasm Metastasis , Neoplasm Proteins/metabolism , Neoplasm Staging , RNA, Messenger/metabolism , Skin/metabolism , Transcription, Genetic
12.
Proc Natl Acad Sci U S A ; 95(8): 4510-5, 1998 Apr 14.
Article in English | MEDLINE | ID: mdl-9539768

ABSTRACT

Considering the well established role of nonclassical HLA-G class I molecules in inhibiting natural killer (NK) cell function, the consequence of abnormal HLA-G expression in malignant cells should be the escape of tumors from immunosurveillance. To examine this hypothesis, we analyzed HLA-G expression and NK sensitivity in human malignant melanoma cells. Our analysis of three melanoma cell lines and ex vivo biopsy demonstrated that (i) IGR and M74 human melanoma cell lines exhibit a high level of HLA-G transcription with differential HLA-G isoform transcription and protein expression patterns, (ii) a higher level of HLA-G transcription ex vivo is detected in a skin melanoma metastasis biopsy compared with a healthy skin fragment from the same individual, and (iii) HLA-G protein isoforms other than membrane-bound HLA-G1 protect IGR from NK lysis. It thus appears of critical importance to consider the specific role of HLA-G expression in tumors in the design of future cancer immunotherapies.


Subject(s)
HLA Antigens/biosynthesis , Histocompatibility Antigens Class I/biosynthesis , Immunologic Surveillance/physiology , Killer Cells, Natural/immunology , Melanoma/immunology , Skin Neoplasms/immunology , Cell Membrane/immunology , Cytotoxicity, Immunologic , DNA Primers , HLA-G Antigens , Humans , Male , Melanoma/pathology , Polymerase Chain Reaction , Skin Neoplasms/pathology , Transcription, Genetic , Tumor Cells, Cultured
13.
Int J Cancer ; 72(6): 987-94, 1997 Sep 17.
Article in English | MEDLINE | ID: mdl-9378563

ABSTRACT

This study investigates the generation of primary melanoma cell-specific cytotoxic T lymphocytes (CTLs) in vitro. Induction of peptide-specific CTLs from unfractionated naive peripheral blood mononuclear cells from HLA-A2 healthy donors was assessed using 2 recently described 9-mer epitopes from the melanoma tumor antigen Melan-A/MART-1. The need for help from CD4+ T lymphocytes for the long-lasting induction of CTLs and the capacity of the peptide-induced CTL lines to recognize many melanoma cells were evaluated. CTL lines were obtained reproducibly when CD4+ T-lymphocyte help was provided during the primary stimulation either in an autologous way, in the case of tetanus toxoid antigen (TT) responder donors, or with allogeneic TT-activated T-helper cells, separated by an insert well, in the case of tetanus toxoid non-responder donors. We also investigated helper T-cell-derived factors that are produced by TT-activated lymphocytes. Our results strongly suggest that a complex network of cytokines like interleukin-2 (IL-2), interferon-gamma, IL-6 and IL-1 exerts stimulatory effects for the initiation process of CTLs. In contrast, cytokine-like IL-4 might inhibit generation of cytolytic activity if provided by TT-activated T cells at early stages of induction. Our approach can be used to generate CTLs of a desired specificity for clinical use in adoptive immunotherapy protocols.


Subject(s)
Antigens, Neoplasm/immunology , Cytokines/biosynthesis , Leukocytes, Mononuclear/immunology , Melanoma/immunology , Neoplasm Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Cells, Cultured , Cytotoxicity, Immunologic , HLA-A2 Antigen/biosynthesis , Humans , Interferon-gamma/biosynthesis , Leukocytes, Mononuclear/cytology , Lymphocyte Activation , MART-1 Antigen , Molecular Sequence Data , Neoplasm Proteins/chemistry , Oligopeptides/chemistry , Oligopeptides/pharmacology , Polymerase Chain Reaction , Receptor-CD3 Complex, Antigen, T-Cell/analysis , Receptors, Antigen, T-Cell, alpha-beta/analysis , T-Lymphocytes, Cytotoxic/cytology , Tumor Necrosis Factor-alpha/biosynthesis
14.
Ann Dermatol Venereol ; 124(6-7): 463-6, 1997.
Article in French | MEDLINE | ID: mdl-9739911

ABSTRACT

INTRODUCTION: Because of the potential hepatotoxicity of retinoids, prescription of isotretinoin is always very carefully made in healthy subjects, and prohibited in case of concomitant hepatopathy. Gilbert's syndrome consists of chronic, mild, unconjugated hyperbilirubinemia. In this syndrome, isotretinoin has been reported twice to be perfectly tolerated, and once even beneficial. We report here a new case of good tolerance and even improvement of a Gilbert's syndrome during isotretinoin therapy. CASE REPORT: A 17-year-old man with Gilbert's syndrome presented with a nodulocystic acne. Topical agents had been inefficient, and cyclines bad tolerated. Thus isotretinoin has been gradually introduced, with a regular monitoring of the liver function. We observed a steady decrease of the bilirubinemia during the course of isotretinoin, and then a reappearance of hyperbilirubinemia as soon as posology was diminished and particularly after completion of isotretinoin therapy. DISCUSSION: A review of the literature finds only very few cases of hepatic injuries caused by isotretinoin, contrary to etretinate. Safety of isotretinoin in Gilbert's syndrome was first observed in 1984, but its beneficial effects have only recently been described by Wang et al., and we report here a similar case. Pharmacological mechanisms remain hypothetic. However, considering the prevalence of Gilbert's syndrome and its usual first expression during postpubertal period, it seems to us interesting for therapeutic practice to know that isotretinoin is not less safe in these patients.


Subject(s)
Gilbert Disease/drug therapy , Isotretinoin/therapeutic use , Keratolytic Agents/therapeutic use , Acne Vulgaris/drug therapy , Adolescent , Bilirubin/blood , Humans , Male
17.
Clin Infect Dis ; 21(3): 680-1, 1995 Sep.
Article in English | MEDLINE | ID: mdl-8527569

ABSTRACT

We report two cases of prolonged fever in deeply immunocompromised patients with AIDS who had been receiving trimethoprim-sulfamethoxazole (TMP-SMZ) as primary prophylaxis for several months. Investigations of the cause of fever yielded normal or negative findings except that the polymerase chain reaction (PCR) for Toxoplasma gondii in the blood was positive in both cases, and PCR of the bronchoalveolar lavage fluid was positive in one case. After a few days of treatment with pyrimethamine plus clindamycin, the two patients became afebrile and the T. gondii PCR became negative. The patients probably had disseminated toxoplasmosis attenuated by TMP-SMZ. PCR examination of blood for evidence of T. gondii genome may be useful in screening for causes of unexplained fever in patients with AIDS, even those who receive prophylaxis with TMP-SMZ.


Subject(s)
AIDS-Related Opportunistic Infections/complications , Antiprotozoal Agents/pharmacology , Fever/etiology , HIV-1 , Toxoplasmosis/complications , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , AIDS-Related Opportunistic Infections/prevention & control , Adult , Animals , Antifungal Agents/pharmacology , Humans , Male , Middle Aged , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/prevention & control , Polymerase Chain Reaction , Time Factors , Toxoplasma/genetics , Toxoplasma/isolation & purification , Toxoplasmosis/prevention & control , Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...